Theralase Technologies Inc. announced its year-end 2011 financial results, reporting stable total revenues of $2,027,058 compared to 2010. Selling expenses increased 55% due to expansion efforts in the US market, while administrative expenses decreased 17%. Research and development costs rose 26% to advance laser and cancer/bacteria destruction technologies. The net loss was $1,453,974 including non-cash expenses, compared to a 2010 net loss of $1,168,350. Subsequent to year-end, Theralase completed a private placement for gross proceeds of $750,000.